November 14-15, 2024
Joseph B. Martin Conference Center
77 Avenue Louis Pasteur, Boston, MA 02115

Cancer treatment has evolved significantly over the past decade from a treatment paradigm anchored on surgery, chemotherapy, and radiotherapy, to one embracing molecularly-targeted therapies disrupting tumor-specific signaling pathways, as well as new approaches to mobilize the immune system. For clinicians trying to keep current with advancing immuno-oncology principles and research, the pace of these developments has brought new challenges. Recognizing these challenges, this two-day CME course, Advances in Cancer Immunotherapy 2024: Annual Update, will provide a comprehensive clinical review of the advances taking place in the immuno-oncology field.

This year we have added an optional session on Immunotherapy Toxicities, focusing on the identification and management of common and uncommon toxicities from immune-checkpoint inhibitors. Attendance at this session, entitled Sink or Swim: Navigating the Murkey Waters of Immunotherapy Toxicities is optional and available for an additional fee. It will take place after the close of the general session on the second day. Attendance at the Advances in Cancer Immunotherapy symposium is NOT required to attend this toxicities session, you may register to ONLY attend this part of the program.

Target Audience

This activity is intended for physicians, nurses, physician assistants, and other members of the healthcare team.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Evaluate cancer immunotherapy principles and strategies and how they influence current treatment approaches.
  • Identify the emerging role of personalized cancer vaccination and other immunotherapy combinations in patients with solid tumor and hematologic malignancies.
  • Define currently approved and emerging predictive biomarkers for cancer immunotherapy.
  • Recognize and implement management strategies for immune-mediated side effects in patients treated with immunotherapy agents.
  • Recognize the importance of establishing a multidisciplinary approach in the immunotherapy era.

Course Directors

Justin Gainor, MD
Ryan Sullivan, MD
Krista Rubin, MS, FNP-BC